首页> 美国卫生研究院文献>Genes >Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans IMPG1 and IMPG2 in Patients with Vitelliform Macular Lesions
【2h】

Mutations in the Genes for Interphotoreceptor Matrix Proteoglycans IMPG1 and IMPG2 in Patients with Vitelliform Macular Lesions

机译:呈粉状黄斑病变的患者间光感受器基质蛋白聚糖IMPG1和IMPG2的基因突变。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A significant portion of patients diagnosed with vitelliform macular dystrophy (VMD) do not carry causative mutations in the classic VMD genes BEST1 or PRPH2. We therefore performed a mutational screen in a cohort of 106 BEST1/PRPH2-negative VMD patients in two genes encoding secreted interphotoreceptor matrix proteoglycans-1 and -2 (IMPG1 and IMPG2). We identified two novel mutations in IMPG1 in two simplex VMD cases with disease onset in their early childhood, a heterozygous p.(Leu238Pro) missense mutation and a homozygous c.807 + 5G > A splice site mutation. The latter induced partial skipping of exon 7 of IMPG1 in an in vitro splicing assay. Furthermore, we found heterozygous mutations including three stop [p.(Glu226*), p.(Ser522*), p.(Gln856*)] and five missense mutations [p.(Ala243Pro), p.(Gly1008Asp), p.(Phe1016Ser), p.(Tyr1042Cys), p.(Cys1077Phe)] in the IMPG2 gene, one of them, p.(Cys1077Phe), previously associated with VMD. Asymptomatic carriers of the p.(Ala243Pro) and p.(Cys1077Phe) mutations show subtle foveal irregularities that could characterize a subclinical stage of disease. Taken together, our results provide further evidence for an involvement of dominant and recessive mutations in IMPG1 and IMPG2 in VMD pathology. There is a remarkable similarity in the clinical appearance of mutation carriers, presenting with bilateral, central, dome-shaped foveal accumulation of yellowish material with preserved integrity of the retinal pigment epithelium (RPE). Clinical symptoms tend to be more severe for IMPG1 mutations.
机译:被诊断为玻璃状黄斑营养不良(VMD)的患者中,有很大一部分在经典VMD基因BEST1或PRPH2中没有引起突变。因此,我们在106名BEST1 / PRPH2阴性VMD患者队列中的两个基因中进行了突变筛选,所述两个基因编码分泌型感光体基质蛋白聚糖1和-2(IMPG1和IMPG2)。我们在儿童期发病的两个单纯性VMD病例中发现了IMPG1中的两个新突变,即杂合p。(Leu238Pro)错义突变和纯合c.807 + 5G>剪接位点突变。后者在体外剪接测定中诱导了IMPG1外显子7的部分跳过。此外,我们发现了杂合突变,包括三个终止位[p。(Glu226 *),p。(Ser522 *),p。(Gln856 *)]和五个错义突变[p。(Ala243Pro),p。(Gly1008Asp),p。 (Phe1016Ser),p。(Tyr1042Cys),p。(Cys1077Phe)],其中之一是p。(Cys1077Phe),先前与VMD相关。 p。(Ala243Pro)和p。(Cys1077Phe)突变的无症状携带者表现出细微的中央凹不规则,这可能是疾病的亚临床阶段的特征。两者合计,我们的结果提供了进一步的证据,证明在VMD病理中IMPG1和IMPG2的显性和隐性突变参与其中。突变携带者的临床表现具有显着相似性,表现为双侧,中央,穹顶状凹状淡黄色物质积聚,并保留了视网膜色素上皮(RPE)的完整性。 IMPG1突变的临床症状往往更严重。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号